Roche Holding AG (OTCMKTS:RHHBY) Receives Average Rating of “Hold” from Brokerages

Roche Holding AG (OTCMKTS:RHHBY) has received a consensus rating of “Hold” from the six research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $40.00.

RHHBY has been the subject of a number of recent research reports. Argus restated a “hold” rating on shares of Roche in a report on Monday, March 4th. Morgan Stanley lowered shares of Roche from an “equal weight” rating to an “underweight” rating in a report on Tuesday, January 16th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. grew its position in shares of Roche by 1,937.5% in the 4th quarter. Pacer Advisors Inc. now owns 1,099,659 shares of the company’s stock worth $39,841,000 after buying an additional 1,045,687 shares during the period. Saratoga Research & Investment Management grew its position in shares of Roche by 19.4% in the 3rd quarter. Saratoga Research & Investment Management now owns 2,268,479 shares of the company’s stock worth $76,969,000 after buying an additional 368,444 shares during the period. Tower Bridge Advisors purchased a new stake in shares of Roche in the 3rd quarter worth about $2,811,000. Ramirez Asset Management Inc. purchased a new stake in shares of Roche in the 3rd quarter worth about $2,575,000. Finally, Cable Hill Partners LLC purchased a new stake in Roche during the 4th quarter valued at about $464,000.

Roche Stock Down 2.2 %

Shares of RHHBY opened at $30.54 on Thursday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.04 and a current ratio of 1.35. Roche has a fifty-two week low of $29.95 and a fifty-two week high of $40.48. The firm has a 50 day moving average price of $31.99 and a 200-day moving average price of $33.68.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.